Back to search
FDAFDA · Food and drugs·Recall number Z-0321-2027

MiSeq Dx Instrument REF: DX-410-1001 / 15036706, FOR IN VITRO DIAGNOSTIC USE

Published November 11, 2026 · Recall initiated: May 8, 2024

Summary

FDA records medical device Class II recall Z-0321-2027, published November 11, 2026 and initiated May 8, 2024. Recalling firm: Illumina, Inc.; Status: Ongoing; Reported quantity: 1193 units; Lot: All Lots/UDI: 00816270020002. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

(Retrospectively reported) Cybersecurity vulnerability identified in communication protocol between the customer-provided infrastructure (network storage, servers, or computers) and in vitro diagnostic devices which may result in compromised data transmission.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Illumina, Inc.
Distributor
Worldwide - US Nationwide distribution including in the states and territory of AL, AR, AZ, CA, CO, CT, DC, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, NE, NH, NJ, NM, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV and the countries of AE, AR, AT, AU, BE, BG, CA, CH, CL, CN, CY, CZ, DE, DK, DZ, EG, ES, FI, FR, GB, Ghana, GR, GT, HK, HU, IE, IL, IS, IT, JP, KR, KW, LT, LU, LV, MA, MT, NG, NL, NO, NZ, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, TH, TR, UA, VN, ZA.
Lot
All Lots/UDI: 00816270020002
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was MiSeq Dx Instrument REF: DX-410-1001 / 15036706, FOR IN VITRO DIAGNOSTIC USE recalled?

Yes. FDA published recall Z-0321-2027 on November 11, 2026. Reported hazard: (Retrospectively reported) Cybersecurity vulnerability identified in communication protocol between the customer-provided infrastructure (network storage, servers, or computers) and in vitro diagnostic devices which may result in compromised data transmission.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail